Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) Dose-Ranging Study

Withdrawn before enrolling · Phase 1

Conditions studied: Diarrhea

In brief

This study is an open-labeled dose escalating trial in which a total of 32 subjects will receive one of four intranasal rFla-MBP vaccine doses.

Key facts

Study ID

NCT00124865

Run by

U.S. Army Medical Research and Development Command

People needed

0

Starts

2005-07-01

Expected to finish

2006-11-01

Last updated by the study team

2017-09-26

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult
• 70% accuracy on comprehension test
• Availability for required visits and telephone follow up

You may not qualify if…

• Pregnancy or breastfeeding
• Chronic health problems
• Abnormalities found on physical examination
• Use of immunosuppressive drugs, such as corticosteroids or chemotherapy
• Positive blood test for HIV-1, hepatits B surface antigen (HBsAG) or hepatitis C virus (HCV)
• Abnormalities found on basic laboratory screening
• Prior exposure to Campylobacter
• Current smoker
• Chronic sinusitis or seasonal rhinitis

Where it is running

• Walter Reed Army Institute of Research — Silver Spring, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.